This introductory course provides a foundational understanding of the Observational Health Data Sciences and Informatics (OHDSI) methodology. Designed for individuals new to OHDSI, this course will cover key concepts such as the OMOP Common Data Model (CDM), standardized vocabularies, and essential software tools.
Clinical trial feasibility – it’s a standard part of recruitment planning and essential for predicting enrollment success. Yet so often it’s easy to get wrong, putting timelines and budget at risk. And whether that’s because there’s too great a focus on quantitative factors – such as volume of patients or number of competing studies – it’s clear that study sponsors and sites can benefit from an enhanced approach. This session will present attendees with a new perspective on feasibility models, featuring an approach that combines quantitative and qualitative characteristics to help accurately ascertain a site’s probability of enrollment success. This session will introduce qualitative factors – such as investigator enthusiasm for the investigational compound and study coordinator motivation / bandwidth – to the feasibility conversation.
BBK Worldwide’s Matt Kibby will present insights drawn from a 20-year career solving enrollment challenges, and he will provide attendees with strategic recommendations for enhanced feasibility and planning. BBK Worldwide’s Jacob Silberstein – a former site coordinator – will bring a feet-on-the-street perspective to the conversation, sharing his experience and insight.
Attendees will learn to evaluate sites’ enrollment potential using criteria such as staffing capacity, recruitment-mindfulness, database mining procedures, patient panel, study appeal, investigator enthusiasm, and the experience, motivation, and bandwidth of the study coordinator.
About BBK Worldwide:
BBK Worldwide is committed to transforming the clinical trial patient experience through a combination of services and technology-driven solutions that educate consumers, engage participants, unburden sites, and support sponsors. One of the few remaining corporately independent and full-service R&D marketing firms, BBK has maintained its position at the forefront of patient recruitment and engagement innovation for more than 35 years. An industry game changer, BBK’s patented smart technology TrialCentralNet® drives the company’s innovation while enhancing the patient journey and supporting the study community. Headquartered near Boston, Massachusetts, BBK has partners and offices across Europe and the Asia-Pacific region. To learn more about BBK Worldwide, please visit BBKworldwide.com.
